235 related articles for article (PubMed ID: 32239429)
21. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
Parikh PK; Ghate MD
Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
[TBL] [Abstract][Full Text] [Related]
23. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
[No Abstract] [Full Text] [Related]
24. Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents.
Guo T; Ma S
ChemMedChem; 2021 Feb; 16(4):600-620. PubMed ID: 33179854
[TBL] [Abstract][Full Text] [Related]
25. PRMT5 as a druggable target for glioblastoma therapy.
Banasavadi-Siddegowda YK; Welker AM; An M; Yang X; Zhou W; Shi G; Imitola J; Li C; Hsu S; Wang J; Phelps M; Zhang J; Beattie CE; Baiocchi R; Kaur B
Neuro Oncol; 2018 May; 20(6):753-763. PubMed ID: 29106602
[TBL] [Abstract][Full Text] [Related]
26. Properties of FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).
Huang L; Jiang S; Shi Y
J Hematol Oncol; 2020 Oct; 13(1):143. PubMed ID: 33109256
[TBL] [Abstract][Full Text] [Related]
28. Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy.
Yin Y; Yuan X; Gao H; Yang Q
Int J Pharm; 2020 Jan; 573():118785. PubMed ID: 31678384
[TBL] [Abstract][Full Text] [Related]
29. EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.
Westphal M; Maire CL; Lamszus K
CNS Drugs; 2017 Sep; 31(9):723-735. PubMed ID: 28791656
[TBL] [Abstract][Full Text] [Related]
30. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
31. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
Alsfouk A
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):693-706. PubMed ID: 33632038
[TBL] [Abstract][Full Text] [Related]
32. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review.
Ranieri G; Pantaleo M; Piccinno M; Roncetti M; Mutinati M; Marech I; Patruno R; Rizzo A; Sciorsci RL
Crit Rev Oncol Hematol; 2013 Nov; 88(2):293-308. PubMed ID: 23768779
[TBL] [Abstract][Full Text] [Related]
33. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms.
Loew S; Schmidt U; Unterberg A; Halatsch ME
Anticancer Agents Med Chem; 2009 Jul; 9(6):703-15. PubMed ID: 19601750
[TBL] [Abstract][Full Text] [Related]
34. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
Steeghs N; Nortier JW; Gelderblom H
Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
[TBL] [Abstract][Full Text] [Related]
35. Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions.
Cerchia C; Lavecchia A
Curr Med Chem; 2017; 24(21):2312-2344. PubMed ID: 28413965
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
Aldaz P; Arozarena I
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830952
[TBL] [Abstract][Full Text] [Related]
37. Caffeine Effect on HIFs/VEGF Pathway in Human Glioblastoma Cells Exposed to Hypoxia.
Maugeri G; D'Amico AG; Rasà DM; Saccone S; Federico C; Magro G; Cavallaro S; D'Agata V
Anticancer Agents Med Chem; 2018; 18(10):1432-1439. PubMed ID: 29424319
[TBL] [Abstract][Full Text] [Related]
38. Stopping cancer in its tracks: using small molecular inhibitors to target glioblastoma migrating cells.
Mattox AK; Li J; Adamson DC
Curr Drug Discov Technol; 2012 Dec; 9(4):294-304. PubMed ID: 22339073
[TBL] [Abstract][Full Text] [Related]
39. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
40. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
